Thymosin Alpha-1 Side Effects: Safety Signals and Warnings
Thymosin Alpha-1 safety concerns are compound-specific. The main listed side effects are Generally well-tolerated, Mild injection site reactions, and Rare flu-like symptoms. The main warning signals are Not FDA-approved in the United States, Should be used with caution in autoimmune conditions, and May potentiate immune responses in transplant recipients.
Direct Answer
Thymosin Alpha-1 (Zadaxin) has Phase 3 data and is approved in over 30 countries for hepatitis B and as a cancer immune adjuvant, though it lacks FDA approval in the US. The hepatitis B evidence base - including 18+ RCTs - is real and reproducible. For immune restoration research in immunocompromised populations or viral hepatitis, thymosin alpha-1 is the best-evidenced peptide immune modulator in this library.
- Evidence grade
- Level B
- Research status
- Approved Outside US
- Category
- Immune Support
- Evidence context
- Hepatitis B/C immune adjuvant therapy, cancer immune support, T-cell restoration in immunocompromised patients
Reported Side Effects
- Generally well-tolerated
- Mild injection site reactions
- Rare flu-like symptoms
- Occasional fatigue
Warnings
- Not FDA-approved in the United States
- Should be used with caution in autoimmune conditions
- May potentiate immune responses in transplant recipients
- Limited pediatric safety data
Known or Plausible Interactions
- Immunosuppressants (may counteract their effects)
- Interferon-alpha (commonly used in combination)
- Chemotherapy agents (used as adjuvant)
Regulatory Context
Thymosin Alpha-1 (Zadaxin) is approved in over 30 countries for hepatitis B and as an immune adjuvant. It is not FDA-approved in the United States but is available as a research peptide. Orphan drug designations have been granted for some indications.
Evidence Snapshot
| Evidence grade | Level B |
|---|---|
| Research status | Approved Outside US |
| Best supported outcomes | Hepatitis B/C Treatment (Level B), Cancer Immune Adjuvant (Level B), and T-Cell Immune Restoration (Level B) |
| Primary citation count | 3 |
| Last reviewed | 2026-08-27 |
Quick Answers
What are the side effects of Thymosin Alpha-1?
Thymosin Alpha-1 safety concerns are compound-specific. The main listed side effects are Generally well-tolerated, Mild injection site reactions, and Rare flu-like symptoms. The main warning signals are Not FDA-approved in the United States, Should be used with caution in autoimmune conditions, and May potentiate immune responses in transplant recipients.
What is the evidence level for Thymosin Alpha-1?
Thymosin Alpha-1 is rated Level B. Its current research status is Approved Outside US.
What is Thymosin Alpha-1 best known for?
Hepatitis B/C immune adjuvant therapy, cancer immune support, T-cell restoration in immunocompromised patients.
Where can I read the full Thymosin Alpha-1 evidence review?
The full evidence review is available at https://examinepeptides.com/library/thymosin-alpha-1.
Related Guides
How to Cite This Page
ExaminePeptides. "Thymosin Alpha-1 Side Effects: Safety Signals and Warnings." Last reviewed 2026-08-27. https://examinepeptides.com/answers/thymosin-alpha-1-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.